

Roche Access to Healthcare

Supported Programs

This table provides an overview of the major programs Roche supports to encourage Access to Healthcare, globally. For further information please visit www.roche.com/access_to_healthcare

Project	Objective	Progress 2010
Accelerating Access Initiative (AAI) http://www.ifpma.org/index.php?id=3754	Increase access to HIV/AIDS medicines in developing countries through our role as a founding member of the AAI, a partnership between nine research-based pharmaceutical companies and five UN agencies.	AAI efforts have led to a growing number of patients receiving treatment in the developing world, as reported by UNAIDS.
AmpliCare www.roche.com/amplicare www.roche.com/sust-diagnostics-access.pdf	Support sustainable HIV/AIDS and Tuberculosis programs in least developed countries (LDCs) and other resource-limited settings. Multifaceted program consisting of: <ol style="list-style-type: none"> 1. provide sustainable diagnostic solutions for Early Infant Diagnosis (EID) of HIV 2. supply HIV viral load tests at sustainably reduced prices for monitoring patients on government ARV program 3. support capacity building initiatives, such as training to healthcare workers and technical staff through our training academies. 	Over 1,100,000 infants have been tested for HIV and ~560,000 patients on HIV/AIDS therapy have had their viral levels monitored. Specifically developed an innovative Dried Blood Spot testing solution for diagnosis and viral load monitoring for patients on therapy, along with the ability to report patient lab results to remote clinics by text message (SMS). Developed a rapid PCR-based MTB assay for screening patients for Tuberculosis, with the possibility to detect resistant strains. Over 100 laboratories are trained annually at our PCR Academy and partner training facilities.
AmpliCare encourages cooperation between private, public and non-profit organisations to improve access and build capacity	Africa - Clinton Foundation HIV/AIDS Initiative (CHAI) Cambodia – Clinton Foundation and the National Centre of HIV/AIDS Dermatology and STI control (NCHADS)	Implemented 8 turn-key lab solutions for HIV testing. 10,000 HIV patients currently enrolled in program to manage HIV treatment, with 1,500 children under treatment. Established a National testing laboratory.

	<p>Thailand - National Health and Security Office (NHSO) collaboration</p>	<p>To date, ~200,000 HIV patients are registered on the NHSO program, with ~130,000 HIV patients undergoing treatment. Through the “Mother to child prevention program”, ~6,000 couples are registered for early infant HIV diagnosis. Established 31 testing laboratories.</p>
	<p>Myanmar – UNICEF</p>	<p>Established a National testing laboratory for early infant diagnosis.</p>
<p>Changing Diabetes in Children</p> <p>www.roche.com/diabetes_in_children.pdf</p>	<p>Build long-term solutions for sustainable diabetes care, including improved awareness, screening, access to treatment, and education and training for healthcare workers, patients and their families on Diabetes.</p> <p>A collaboration with Novo Nordisk, the World Diabetes Foundation (WDF) and several African governments, the project aims to improve the lives of children with diabetes in developing countries.</p>	<p>More than 450 children have been enrolled in sub-Saharan Africa (sSA) in the program. Through our partnership, the children received education in diabetes care and access to insulin and diabetes testing supplies.</p> <p>We participated in workshops for healthcare workers in Cameroon and Uganda, as well as in the Diabetes Leadership Forum Africa 2010, attended by over 260 participants from 32 sSA countries.</p>
<p>Clinical trial programmes</p> <p>www.roche.com/clinical_trials</p>	<p>Provide free medicines and tests to patients in phase I-IV clinical trials, often including additional treatments alongside those being trialled. We compensate hospitals and clinics for hosting the trials and encourage them to use the money to fund additional nursing staff, education centres and research.</p>	<p>Nearly 330,000 patients worldwide gained access to innovative treatments by taking part in any of our phase I-IV trial programs.</p>
<p>Clinical trial protocol registry and trial results database</p> <p>www.roche-trials.com www.clinicaltrials.gov www.ifpma.org/clinicaltrials</p>	<p>Share information and key results about Roche-managed trials with patients and healthcare providers. Roche logs trial data into an independently run site, (roche-trials.com), plus the US National Institutes of Health’s Clinical Trials Registry and on the International</p>	<p>Roche has published 842 protocols and 385 trial results since the programs launch in 2005.</p> <p>Roche-trials.com had 194,241 visits in 2010.</p>

	Federation of Pharmaceutical Manufacturers and Associations (IFMA) clinical trials portal.	
EDUCARE www.roche.com/educare	Improve cancer care in Africa by joining forces with the International Atomic Energy Agency (IAEA) to launch EDUCARE in 2010. The program aims to establish an online university offering comprehensive training in several areas of cancer management, and a network for doctors to share knowledge and experience with their peers.	In 2010 we identified suitable sites for pilot programs in Ghana, Zambia, Tanzania, and Uganda, where we will begin training programs in 2011.
Google.org partnership	Predict and prevent emerging infectious diseases in East Africa through a partnership formed in 2009 with the philanthropic arm of Google.	Roche donated a genome sequencing system to the International Livestock Research Institute Laboratory in Nairobi, Kenya.
Institute of OneWorld Health (iOWH) collaboration www.oneworldhealth.org	Increase research into neglected diseases through collaboration. Since 2008, the partnership enables iOWH to screen compounds from the Roche library to identify new drugs for treating acute diarrhoea.	iOWH completed the first screening, identifying 40 compounds to investigate as possible new treatments.
Pandemic planning http://www.roche.com/media/media_releases/med-cor-2009-07-01.htm	Ensure adequate worldwide stocks of the Roche influenza drug Tamiflu for pandemic stockpiling. Pandemic plan developed in 2004, in conjunction with the WHO, which included appropriate production and distribution channels. Licensed companies in India and China and to produce generic oseltamvir, and offered governments substantially reduced prices for their own stockpiles.	Donated around 11 million treatment courses of Tamiflu, including a supply of 650,000 paediatric treatment courses. The Tamiflu Reserves Programme was introduced in 2009 to further increase access in developing countries.
Patent and pricing policies www.roche.com/sustainable_patent_pricing_policies	Enable access to our medicines in the world's Least Developed (LDCs) and Low Income Countries (LICs) by not enforcing existing patents or applying for new patents in these countries. In addition, we supply two HIV medicines at no-profit prices in the LDCs and sub-	Roche's no-profit prices for our HIV medicines apply to more than 22 million people in 55 countries, covering 68% of all people living with HIV/AIDS.

	Saharan Africa (sSA), and at reduced prices in lower-middle-income countries (LMICs). We provide Valcyte, our medicine for AIDS-related CMV infection, at reduced prices in the LCDs, LICs, sSA and LMICs.	Including low- and lower middle-income countries, we offer reduced prices for our HIV medicines to 83% of all people living with HIV/AIDS.
<p>Patient assistance programs</p> <p>www.gene.com/gene/products/access</p>	Help insured patients in the USA navigate the complexities of health insurance coverage and find payment support programs where possible, through Genentech Access Solutions (GAS). Provide free medicines to uninsured and underinsured patients who meet certain financial and medical criteria through the Genentech Access to Care Foundation (GATCF).	In 2010, GAS assisted more than 107,000 people and GATCF provided free medicines to more than 47,000 patients.
<p>Technology Transfer Initiative</p> <p>www.roche.com/technology_transfer_initiative</p>	Provide companies in Least Developed Countries and sub-Saharan Africa with free, on-site technical help to manufacture generic versions of Roche's HIV medicine, saquinavir. This program was launched in 2006.	Roche assessed and provided on-site support and guidance to 39 manufacturers, and signed transfer agreements with 13 companies in 6 countries, who are now free to produce generic saquinavir.
<p>Transnet-Phelophepa Healthcare train</p> <p>www.roche.com/transnet-phelophepa_healthcare_train</p> <p>www.react.roche.com/health-care-train.htm</p>	Deliver medical care to remote parts of South Africa through a mobile clinic – the Transnet-Phelophepa healthcare train. Phelophepa is owned and operated by Transnet, with Roche the principle sponsor. The train's 18 coaches are equipped to provide general health, dental, eye and psychiatric care as well as cancer screening tests, diabetes prevention and counselling sessions. In addition it provides community education on general health issues, such as hygiene and nutrition, as well as an outreach program visiting local schools and villages to deliver vital health checks, medicines and education.	<p>Since its launch in 1994, around 600,000 people have received treatment in the train's various clinics. A further 1.3 million people have attended school screening, health education and counselling workshops, and over 5 million have benefited from general screening, HIV/AIDS awareness, health education and outreach programs.</p> <p>In 2010, Roche refurbished the primary health coach, improving ventilation, privacy and disabled access.</p>

<p>WHO Special Program for Research and Training in Division for Tropical Diseases</p> <p>apps.who.int/tdr apps.who.int/tdr/svc/grants/calls/cdf</p>	<p>Help train the WHO Division for Tropical Diseases (TDR) researchers, clinical monitors and ethics committees in compliance, good clinical practice and quality assurance.</p>	<p>Roche led a series of auditing and quality assurance workshops for researchers managing and monitoring WHO sponsored trials on tropical diseases. We also supported training events in sub-Saharan Africa and Asia Pacific, audited WHO trials of leishmaniasis, pulmonary TB and trypanosomiasis, and participated in surveys of ethics committees.</p>
--	--	---

* Classified by United Nations (<http://www.un.org/special-rep/ohrls/lhc/list.htm>)